Stock Detail
MOMENTA PHARMACEUTICALS INC
Biotechnology
MNTA @ Yahoo Finance | MNTA Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $14.78 | $15.20 | $-0.17 | -1.14% | 0.00 | $14.95 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $14.82 | $14.74 | 438,448 | 751.3M | 1.21M | 3.38 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 15.37 | 15.08 | 14.91 | 14.62 | 14.45 |
Stock Profile
Momenta Pharmaceuticals, Inc. engages in structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company's products include M-Enoxaparin, a technology-enabled generic version of Lovenox and a low molecular weight heparin(LMWH), which is used to prevent and treat deep vein thrombosis and treat acute coronary syndromes; M-Dalteparin, also a technology-enabled generic version of the LMWH Fragmin. It also offers Glycoproteins, M118, pulmonary delivery of proteins, and sugar therapeutic, which are in preclinical stages. The company has collaboration agreements with Sandoz and Siegfried, Inc. and Siegfried, Ltd. The company was founded by Ganesh Venkataraman in 2001 as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in 2002. Momenta is based in Cambridge, Massachusetts.